Aplastic anemia (AA) is rare disorder of bone marrow failure which if severe and not appropriately treated is highly fatal. AA is characterized by morphologic marrow features, namely hypocellularity, and resultant peripheral cytopenias. The molecular pathogenesis of AA is not fully understood, and a uniform process may not be the culprit across all cases. An antigen-driven and likely autoimmune dysregulated T-cell homeostasis is implicated in the hematopoietic stem cell injury which ultimately founds the pathologic features of the disease. Defective telomerase function and repair may also play a role in some cases as evidenced by recurring mutations in related telomerase complex genes such as TERT and TERC. In addition, recurring mutations in BCOR/BCORL, PIGA, DNMT3A, and ASXL1 as well as cytogenetic abnormalities, namely monosomy 7, trisomy 8, and uniparental disomy of the 6p arm seem to be intimately related to AA pathogenesis. The increased incidence of late clonal disease has also provided clues to accurately describe plausible predispositions to the development of AA. The emergence of newer genomic sequencing and other techniques is incrementally improving the understanding of the pathogenic mechanisms of AA, the detection of the disease, and ultimately offers the potential to improve patient outcomes. In this comprehensive review, we discuss the current understanding of the immunobiology, molecular pathogenesis, and future directions of such for AA.
| INTRODUC TI ON
Bone marrow failure is a characteristic finding in a number of inherited syndromes such as dyskeratosis congenita, Fanconi anemia, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome; however, acquired etiologies of marrow aplasia may present similarly. 1, 2 Originally described by Dr. Paul Ehrlich in 1888 and further defined by 1904 by Dr. Anatole Chauffard, aplastic anemia (AA) is a nonmalignant hematologic disorder characterized by an injured, markedly hypocellular, and thus ineffective bone marrow. 3 The resultant pancytopenia presents diagnostic challenges and confers an extreme risk of mortality when dedicated treatment is not considered. Multiple etiologies for AA have been proposed which in due course lead to an immunemediated destruction of hematopoietic stem cells (HSCs) residing in the bone marrow, but the bulk of cases remain idiopathic.
Allogeneic stem cell transplantation (alloSCT) offers much of the limited prospect of cure for patients (who do not respond to immunosuppressive therapy), but unfortunately a significant subset of patients are not suitable candidates. Immunosuppressive therapies otherwise continue to be the mainstay for patients with AA not proceeding to alloSCT, but the increasing understanding of the pathophysiology of HSC injury is expected to incrementally broaden therapeutic options.
| E TI OLOGY AND ANTI G ENI C E XP OSURE
Aplastic anemia is rare disease with an incidence of approximately two to three cases per million per year based on dedicated studies, but may be threefold higher in Asian populations. It is a disease of the young and typically that of the first three decades of life with a median age of about 20 years old, though a second peak occurs around age 60. [4] [5] [6] [7] Geographic differences in incidence implicate environmental and host-related factors and ultimately corroborate prior study into possible causative factors. Etiologic association with occupational exposure to chemical haptens such as benzene and pesticides, specifically the organochlorines and organophosphates has been demonstrated, although these are exceedingly rare causes of AA when examining cases worldwide. [7] [8] [9] In Asian populations specifically, exposure to not only similar pesticides, but also animal fertilizer and animals themselves have been linked to AA. 10, 11 Medication exposures with subsequent idiosyncratic reactions are archetypal (yet still rare) causes of AA-related marrow failure. Chloramphenicol is a classic example which is still without a known, culprit mechanism, although the myelosuppressive effect is attributed to mitochondrial injury. The etiology of resultant AA has been attributed to accumulation of drug metabolites toxic to HSCs. 12, 13 Ocular chloramphenicol and the antiepileptics carbamazepine and valproic acid have been implicated as a cause of AA, although these are likewise exceedingly infrequent. 14, 15 A handful of other supposed offending medications are limited to case reports only.
Aplastic anemia has also been associated with pregnancy, which interestingly enough was also the purported cause for the development of AA of the case first described by Dr. Paul Ehrlich. 3, 16, 17 Infection with human immunodeficiency virus (HIV) is associated with the development of AA, although this association is limited to case reports and small case series which may be a result of a decreasing incidence of HIV infection. 18, 19 Seronegative hepatitis has been implicated in approximately 5% of AA cases. 20, 21 Association with eosinophilic fasciitis is limited to less than two dozen cases reported in the literature, although many patients have concomitant autoimmune disorder and/or possible environmental exposure which could otherwise be implicated. 22, 23 Clear infectious etiologies beyond hepatitis and HIV have yet to be established and be confounded by the fact that undiagnosed postinfectious aplasia can be clinically mistaken for AA.
| THE PATHOG ENIC IMMUNOB IOLOGY
The injury to hematopoiesis observed in AA has primarily been shown to be facilitated by an antigen-driven immune response, which may be related to the suspected etiologic factors discussed previously. The broad and heterogeneous nature of these associated etiologic factors may call into question whether a single mechanism is responsible for the resultant profound cytopenias with which AA manifests. In fact, several pathophysiologic pathways have been proposed to explain the pathologic nature of the disease, but the greatest proportion of cases is hypothesized to be a result of uniform T cell-mediated autoimmunity and marrow destruction leading to defective and nearly absent hematopoiesis. Strong laboratory data suggest that suspected yet unidentified antigenic exposure leads to a polyclonal expansion of CD4+ T cells dysregulation at the genetic level and ultimately an overproduction of proinflammatory cytokines such as interferon (IFN)-γ as well as tumor necrosis factor (TNF)-α. Oligoclonal expansion of a dysregulated cytotoxic CD8+ Tcell population has also been demonstrated in ex vivo bone marrow models of AA patients. [24] [25] [26] [27] Increases in T helper 17 (Th17) cells, the effector cells which produce the proinflammatory cytokine interleukin-17 (IL-17), are also found in the peripheral blood and bone marrow of AA patients. 28 The degree of Th17 cell elevation in one study was also found to correlate with the amount of IFN-γ-producing cells and overall disease activity; Th17 cell populations also negatively correlated with Treg populations. 28 The concept of aberrant, disordered T-cell populations initiating the pathology of AA is also supported by the finding that that T cell-directed immunosuppressive therapy (IST) such as the combination of antithymocyte globulin and cyclosporine is able to induce response in up to 80% of patients with severe aplastic anemia. miR-126-5p is also found to be decreased in patients with AA responding to IST, suggesting miRNA interference of cytokine and growth factor-related proinflammatory and immune signaling. 41 
| TELOMERE HOMEOS TA S IS PATHOLOGY
Inherent HSC biological flaws are also suspected to play a role in the pathogenesis of AA. Defective homeostasis of telomeres (the repetitive sequences of DNA which cap linear chromosomes and facilitate cell proliferation) has also been implicated in a significant subset F I G U R E 1 Immunopathogenic mechanism of hematopoietic stem or progenitor cell apoptosis in the aplastic anemia bone marrow of AA patients and is an emerging category of disease in general.
Telomere shortening (occurring if suppressor or other protective genes are inactivated or by physiologic attrition) leads to cell proliferative arrest and eventual apoptosis. 42 To combat the attrition, germ line cells utilize telomerase reverse transcriptase (TERT), telomerase RNA component (TERC), and the stabilizing protein dyskerin (DKC1) to assemble the telomerase complex and maintain telomere length, which is naturally and expectantly lengthy in HSCs. 42 Human lymphocytes are the primary somatic cells which can upregulate
TERT with resultant telomerase activity and provide a transient proliferative advantage, although this does not avert eventual replicative senescence. 43, 44 Approximately 35% of AA patients are found to have peripheral granulocyte and mononuclear cell telomere length shortening, pointing toward a progenitor cell defect. 45, 46 Critical loss of HSC telomere length in about 9% of acquired AA cases has been associated with mutations in TERC, TERT, and DKC1 which are known to be the cause of inherited or constitutional aplastic anemia such as dyskeratosis congenita. 47, 48 Rare mutations in other telomerase genes such as TERF1 and TERF2 have been identified as possible driver mutations in AA. 49 Biallelic mutations in regulator of telomere elongation helicase 1 (RTEL1), which encodes a protein critical to telomere homeostasis, is a known cause of congenital bone marrow failure, but has been identified in 1%-2% of AA cases; most RTEL1 variants, however, are felt not to be pathogenic in the latter condition. 50 The degree of telomere length shortening or erosion has been shown to correlate with the severity of AA, risk of relapse, overall survival, and risk of clonal evolution (via acquisition of new cytogenetic aberrancy) to conditions such as myelodysplastic syndrome (MDS), which will be discussed in more detail later. 51 Telomere length shortening in cases of AA is likely insufficient to lead to AA and ultimately calls into question the distinction between acquired and inherited bone marrow failure syndromes such as AA given it frequently occurs in adult patients without a clear family history of such.
Sex hormones have been shown to exert significant effects on telomere homeostasis. Previous in vitro evidence has shown that HSC exposure to several types of androgens induced telomerase activity and this correlated with higher levels of TERT mRNA. 52 This effect was also seen in peripheral blood lymphocytes heterozygous for loss-of-function TERT mutations which at baseline were associated with reduced telomerase, but with the addition of androgen were restored to normal. 52 Subsequent murine models corroborated this observation of androgen-induced telomere lengthening with eventual improved hematopoiesis. 53 This was ultimately confirmed in human studies using danazol, a strong androgen receptor agonist which increased telomerase activity and correlated with upregulation of TERT. 54 However, a recent retrospective study found no difference in the telomere attrition rates of androgen-treated or untreated patients with dyskeratosis congenita irrespective of the type of androgen therapy used or leukocyte subset evaluated; such data imply a mechanism of clinical response other than androgen-related effects on telomere homeostasis. 55 It remains to be seen whether or not abrogation of telomere length shortening seen in AA (and the foreseeable chromosomal instability) with androgen therapy averts the molecular pathogenesis of clonal evolution.
| THE MYS TERI OUS ROLE OF THROMBOP OIE TIN
Increasing data support the role of thrombopoietin (TPO) and TPO signaling in hematopoiesis specifically related to HSC homeostasis, proliferation, and survival. Knockout murine models lacking the cmpl gene (which encodes the TPO receptor which itself is also expressed on HSCs) show significant deficiencies in HSCs and thus suggest that TPO is integral to HSC homeostasis. 56, 57 Higher levels of plasma TPO are observed in AA patients at diagnosis suggesting a physiologic response to the diminished hematopoiesis and thrombopoiesis. In addition, TPO levels decrease after response to IST. as well as overall response and complete response rates of up to 94% and 58%, respectively, was observed. 62 Similarly, the TPO mimetic romiplostim has been shown to stimulate primitive HSC, augment their differentiation into later progenitor cells, and ultimately demonstrate efficacy in patients with AA refractory to IST. [63] [64] [65] Despite prior theoretical concerns, romiplostim therapy in AA has not been shown to increase the subsequent development of cytogenetic abnormalities or clonal evolution. The most commonly involved region by acquired CN-LOH in AA is the short arm of chromosome 6 at the site of the MHC locus, occurring in about half of AA patients with acquired 6pUPD (Table 1) .
| C Y TOG ENE TI C AB NORMALITIE S AND THE IMMUNE MECHANIS M
6pUPD may develop via the immune-escape of such HLA-deficient
HSCs. 78 In a recent study combining targeted deep sequencing of class I HLA and SNP array in AA patients, 17% ( [85] [86] [87] Other than PIGA mutations, the most frequently detected somatic mutations in AA are in that in BCOR, BCORL1, and the MDS-related somatic mutations in DNMT3A and ASXL1, which in one study cumulatively accounted for 77% of all somatic mutation-positive patients.
| S O M ATI C M UTATI O N S
About a third of AA patients have multiple, independent mutations, including that of the same gene, which supports a stout mechanism by which such clones are selected for expansion and evolution. 72, 87 Median variant allelic frequency (VAF) seems to range from 9% to 20% based on two strong studies detecting such, and three-quarters of all detected somatic mutations have a VAF of <10%. 69, 72 Although less common, recurring mutations in JAK2/JAK3, RUNX1, TP53, CSMD1, and TET2 have been recognized. 72 Rare (in <3% of acquired AA cases collectively) mutations in SRSF2, U2AF1, ERBB2, and MPL were identified in one of the more robust studies using NGS and array-based karyotyping of AA patients to date (Table 2) . 72 Yoshizato et al 72 also demonstrated a dominance of cytosine to thymine transition at CpG dinucleotides and a predilection for nonsense, frameshift, and splice-site alterations. Interestingly, the simple presence of an acquired somatic mutation (other than that of telomere maintenance genes such as TERT and TERC) has been associated with shorter telomere length by a mechanism hypothesized to be the result of hematopoietic stress. 69 As with cytogenic abnormalities, outcomes in AA patients seem to be influenced by the presence of specific somatic mutations.
Mutations in PIGA, BCOR, and BCORL1 are associated with better response to IST as well as improved PFS and OS, while AA patients with mutated DNMT3A, ASXL1, JAK2/JAK3, or RUNX1 fare worse with regard to IST response and survival. 69, 72, 88 AA patients with mutations in DNMT3A or ASXL1 are shown to exhibit a 40% chance of developing MDS, which is far more significant than the observed 10% incidence of such in AA patients in general. 69, 72, 89 Primary or founder clones in AA appear to be consistently small at diagnosis, but clone sizes have been shown to be dynamic and fluctuate without evidence of progression to MDS or AML or even worsened phenotypic disease. In some cases, initially detectable mutations (specifically those clones with BCOR/BCORL or PIGA mutations) can even subsequently evade measurement during the disease course. 72 The acquisition of new secondary or subclones (which can be a product of the original or dominant HSC clone) has also shown to be variable, ranging from no appreciable clinical impact to (in the case of clones with mutated ASXL1 or DNMT3A) a substantial TA B L E 2 Frequently mutated genes in acquired aplastic anemia increase in clone size and even an occult metric preceding progression to malignant myelopoiesis. ASXL1 and DNMT3A and to a lesser degree RUNX1 and U2AF1 clone sizes tend to increase through the course of disease. 72 Because of a lack of consistent predictability and definitive understanding of clonal selection, most AA experts recommend not basing therapeutic decision-making on the presence or size of clonal disease, although specific somatic mutations may raise suspicion. 90 
| E VIDEN CE IN CLONAL E VOLUTI ON AND QUE S TIONS FROM CLONAL HEMATOP OIE S IS
Although AA is considered to be a nonmalignant disease with potential cure using IST or alloSCT, it can be complicated by the development of late clonal disease. This manifestation may provide insight as to further molecular or other biological pathogenic mechanisms of AA development. AA patients have a higher incidence of AML and MDS, namely 7% and 10%, respectively, at 11-year follow-up after receiving IST. 91 The increased prevalence of late clonal complications like MDS and paroxysmal nocturnal hemoglobinuria (PNH) in AA suggests a link between clonal hematopoiesis (CH) and AA. 
MDS (hMDS). hMDS comprises approximately 15% of MDS cases
and is characterized by bone marrow cellularity <30% in patients aged <70 years or <20% cellularity in those older than age 70 years. 93 The impossibility of morphologically distinguishing AA from hMDS has led many experts to identify this phenomenon as an overlap syndrome. A retrospective study of hMDS patients revealed that 62% of patients had normal cytogenetics and only 21% had mutations in either ASXL1, DNMT3A, or BCOR; the overwhelming majority of hMDS patients with a somatic mutation had a prior history of AA. 
| FUTURE D IREC TI ON S
There has been noticeable progress in dissecting the underlying and This would ultimately provide a suitable animal model to study AA in vitro as well as a therapeutic window by means of correcting genetic mutations via gene editing. 101, 102 Eventually, the above should produce a more precise ability to distinguish founder mutations among other acquired subcloncal populations and those that arise with age. Such may afford the ability to predict clinical outcomes of AA patients and thus allow a more appropriate algorithm for therapeutic decisions including allogeneic stem cell transplantation.
| CON CLUS ION
The pathogenesis of AA is directly related to the destruction of he- 
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